SEC Tracker
Get the app
VERA · XBRL financial data

Vera Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VERA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development16,10020,785*23,20029,31140,31433,347*41,27858,19556,47359,310*86,01160,080
General and administrative5,6566,243*7,9128,0329,48715,567*15,91621,94627,45934,896*39,12152,410
Total operating expenses21,75627,028*31,11237,34349,80148,914*57,19480,14183,93294,206*125,132112,490
Operating income (loss)(21,756)(27,028)*(31,112)(37,343)(49,801)(48,914)*(57,194)(80,141)(83,932)(94,206)*(125,132)(112,490)
Interest income2,1581,960*4,1865,1044,7616,663*6,9066,3205,7365,517*6,3555,348
Interest expense9431,056*1,9061,9121,9361,871*1,7921,8741,9601,904*1,8231,848
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(20,104)(25,655)*(28,383)(33,708)(46,632)(43,425)*(51,694)(76,531)(80,293)(91,097)*(121,032)(109,473)
Earnings per share, basic USD per share(0.45)(0.58)*(0.56)(0.62)(0.85)(0.72)*(0.81)(1.20)(1.26)(1.39)*(1.69)(1.52)
Earnings per share, diluted USD per share(0.45)(0.58)*(0.56)(0.62)(0.85)(0.72)*(0.81)(1.20)(1.26)(1.39)*(1.69)(1.52)
Weighted average shares, basic thousands of shares44,36344,435*50,97254,72954,89860,654*63,67263,78963,84765,610*71,47771,838
Weighted average shares, diluted thousands of shares44,36344,435*50,97254,72954,89860,654*63,67263,78963,84765,610*71,47771,838

Balance sheet

CSV

Fiscal quarters (VERA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents27,44145,68169,10525,08527,25692,64655,09049,12157,773354,725114,35148,876
Marketable securities132,498115,035334,559359,302326,053548,206534,744507,706439,616359,864482,409450,285
Marketable securities, non-current1311——————————
Prepaid and other current assets11,68111,30712,70610,36010,82210,36616,24214,52713,92214,29419,04228,332
Total current assets171,620172,023416,370394,747364,131651,218606,076571,354511,311728,883615,802527,493
Property and equipment, net3492811553689601,0621,1511,1551,374945813
Right-of-use asset3,4812,9492,4321,9293,9213,3722,9152,4712,0361,9231,8061,687
Total assets175,618175,546419,356397,291368,560655,681610,167578,528517,503734,733621,739532,984
Accounts payable12,30011,1185,2094,6644,6027,6659,26213,15717,95021,89813,90914,573
Accrued liabilities9,8038,7497,05911,63819,99016,22311,44119,54223,45731,00831,24033,748
Total current liabilities24,62122,30314,54318,41826,46425,37121,89433,55441,88053,45545,14948,321
Lease liability, non-current1,9621,3959194552,5682,4682,3662,2332,0951,919——
Total liabilities51,91173,86165,81469,42279,50278,52675,168110,251118,623130,212122,042125,226
Accumulated deficit(283,447)(309,102)(337,485)(371,193)(417,825)(461,250)(512,944)(589,475)(669,768)(760,865)(881,897)(991,370)
Total stockholders' equity123,707101,685353,542327,869289,058577,155534,999468,277398,880604,521499,697407,758
Total liabilities and equity175,618175,546419,356397,291368,560655,681610,167578,528517,503734,733621,739532,984
Common shares outstanding (cover page) thousands of shares44,433—54,70154,82863,323—63,77463,82463,928—71,78372,063

Cash flows

CSV

Fiscal quarters (VERA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(20,104)(25,655)*(28,383)(33,708)(46,632)(43,425)*(51,694)(76,531)(80,293)(91,097)*(121,032)(109,473)
Stock-based compensation2,923*3,221*4,1244,873*5,588*6,217*7,7449,472*9,745*10,965*13,20815,863*
Depreciation and amortization6*4*1115*24*55*85119*129*135*140132*
Net cash from operating activities(22,973)*(25,144)*(33,830)(24,782)*(36,885)*(39,182)*(54,406)(54,798)*(61,906)*(69,994)*(106,500)(100,253)*
Purchases of property and equipment0*63*089*238*645*187208*133*102*230*
Net cash from investing activities16,228*18,556*(219,286)(22,677)*38,317*(221,383)*15,31728,544*69,761*80,664*(137,816)32,860*
Share repurchases—0*———0*———0*——
Net cash from financing activities297*24,828*276,5403,439*739*325,955*1,53320,285*797*286,282*3,9421,918*
Net change in cash(6,448)*18,240*23,424(44,020)*2,171*65,390*(37,556)(5,969)*8,652*296,952*(240,374)(65,475)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Vera Therapeutics48,876not reported(100,253)*72.1M5.0 quarters 10-QJun 30, 2026
Ani Pharmaceuticals360,212266,04456,669*not reported— 10-QJun 30, 2026
Celldex Therapeutics47,45422(57,410)*78.5M12.5 quarters 10-QJun 30, 2026
Travere Therapeutics123,542224,56398,204*96.0M— 10-QSep 30, 2026
Innoviva570,388119,59151,972*72.2M— 10-QJun 30, 2026
Adaptive Biotechnologies169,87371,553(6,400)*159.6M53.8 quarters 10-QJun 30, 2026
Arrowhead Pharmaceuticals54,75975,253(177,469)*141.3M9.0 quarters 10-QJun 30, 2026
Mannkind52,929109,374(18,371)*321.5M6.0 quarters 10-QJun 30, 2026
Schrodinger287,85358,889(34,070)*not reported12.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.